Shire and Sangamo break up their gene-editing partnership

Damian Garde Shire and Sangamo Biosciences are going their separate ways after three-plus years of collaboration in gene editing, with each company hanging on to the programs best aligned ...

Valeant doubles size of its HQ as deal spree continues

Carly Helfand Serial buyer Valeant is expanding quickly, and to keep up, it's expanding its office space, too. The Canadian pharma has leased another 310,000 square feet at Somerset ...

Tesaro gets a green light for rolapitant, triggering Merck showdown

John Carroll The FDA has given Tesaro a green light to start marketing rolapitant to help prevent some of the common side effects of chemotherapy. And now Tesaro will wage a David-vs.-Goliath ...

More grist for PCSK9 fight as Amgen sets up EU to pay about half as much as U.S.

Tracy Staton Last week, Amgen won its much-anticipated FDA approval for the PCSK9 cholesterol-fighter Repatha and promptly set a price of $ 14,100 per year. But even after pharmacy ...

Adaptimmune pockets GSK payouts after tripling size of TCR trial

Nick Paul Taylor Adaptimmune has bagged two milestones from GlaxoSmithKline. The checks landed in Adaptimmune's bank account after it tripled the size of a Phase I/II synovial sarcoma ...

Report: Baxalta’s $2B plot to buy Ariad broke down over price

Damian Garde Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's ...

Boehringer touts Pradaxa antidote data as FDA decision nears

Carly Helfand LONDON–Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker ...

After partnering with Big Pharmas, Incyte bags its own PD-1 drug in $795M deal

John Carroll After signing up for combo studies with all the leaders in the checkpoint inhibitor race, Incyte has found a checkpoint program for itself. FierceBiotech News

Report: Real-world Blincyto spending likely to fall far short of Amgen’s $178K list price

Tracy Staton When Amgen rolled out its Blincyto treatment for an ultra-rare form of leukemia, the California biotech set what seemed to be an eye-watering price–$ 178,000 ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS